Atika Capital Management LLC Has $11.35 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Atika Capital Management LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 12.0% in the 4th quarter, HoldingsChannel reports. The firm owned 71,700 shares of the medical research company’s stock after acquiring an additional 7,700 shares during the period. Natera makes up approximately 1.2% of Atika Capital Management LLC’s holdings, making the stock its 22nd largest holding. Atika Capital Management LLC’s holdings in Natera were worth $11,350,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the business. Principal Securities Inc. boosted its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its stake in Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after acquiring an additional 61 shares in the last quarter. Silver Oak Securities Incorporated grew its holdings in Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after purchasing an additional 89 shares during the period. Blue Trust Inc. increased its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Finally, Hanseatic Management Services Inc. raised its holdings in shares of Natera by 12.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock valued at $158,000 after purchasing an additional 107 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other news, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 4,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the sale, the director now owns 9,704 shares in the company, valued at $1,433,183.76. This represents a 29.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 325,922 shares of company stock worth $51,603,664 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Stock Down 3.5 %

Shares of NASDAQ:NTRA opened at $133.87 on Friday. Natera, Inc. has a 1 year low of $83.13 and a 1 year high of $183.00. The company has a market capitalization of $18.10 billion, a PE ratio of -76.06 and a beta of 1.80. The business has a fifty day moving average price of $156.81 and a two-hundred day moving average price of $151.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NTRA. Barclays assumed coverage on Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price for the company. JPMorgan Chase & Co. upped their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. BTIG Research reiterated a “buy” rating on shares of Natera in a report on Friday, February 28th. Sanford C. Bernstein boosted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Finally, Piper Sandler raised their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.